home All News open_in_new Full Article

CHEK Proyeksi Pertumbuhan 2026 Didorong Bisnis Genomic Sequencing

JPNN.com, JAKARTA - Bisnis genomic sequencing menjadi penggerak utama pertumbuhan PT Diastika Biotekindo Tbk (CHEK). Sepanjang 2025, produk Genomic Sequencing perusahaan mengalami pertumbuhan tahunan sebesar 136 persen, didorong peningkatan permintaan dari institusi kesehatan dan riset.


today 18 h. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 2041554734
Add Watch Country

arrow_drop_down